Xperience in Orthopedics this week, page-8

Firstly, the US is such a litigious business environment it's pretty difficult to avoid litigation. Furthermore, disrupters generally attract more litigation than slow movers. That NXS have attracted these 2 cases signals that they are prepared to disrupt. That should be a good signal.
Secondly, this is not a stock to make a quick buck on. It's long term, because a) medicos take a long time to be convinced of new technologies especially one that aims to set a "new standard of care". A treatment that turns on its head everything they've done in the past takes some convincing. b) the largest shareholder Lang Walker (at 36%) is a long game player. He didn't accumulate his billions day trading. And someone like that generally doesn't suffer fools lightly either. If Judith was a fool, she'd be long gone.